Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: A population-based study

被引:29
作者
Booth, Christopher M. [1 ,2 ]
Siemens, David Robert [2 ,3 ]
Peng, Yingwei [1 ,4 ]
Mackillop, William J. [1 ,2 ,4 ]
机构
[1] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada
[2] Queens Univ, Dept Oncol, Kingston, ON, Canada
[3] Queens Univ, Dept Urol, Kingston, ON, Canada
[4] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada
基金
加拿大创新基金会;
关键词
Bladder cancer; Quality of care; Chemotherapy; Surgery; Health services research; Knowledge translation; ADJUVANT CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; CYSTECTOMY; CARE;
D O I
10.1016/j.urolonc.2014.05.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Reasons for low uptake of perioperative chemotherapy for muscle-invasive bladder cancer are not well described. Herein, we report referral patterns from urology to medical oncology (MO) in Ontario, Canada, and subsequent use of chemotherapy. Methods: Electronic treatment records were linked to the Ontario Cancer Registry to describe referral patterns and use of neoadjuvant/ adjuvant chemotherapy (NACT/ACT) among patients with muscle-invasive bladder cancer treated with cystectomy in Ontario from 1994 to 2008. Logistic regression identified factors associated with referral to MO and use of NACT/ACT. Results: Overall, 18% (520/2,944) of patients were seen by MO before cystectomy, and 25% (128/520) of referred cases were treated with NACT. Among patients not treated with NACT or radiation, 39% (1,085/2,809) were seen by MO following cystectomy; 51% (548/ 1,085) of referred patients had ACT. There was wide geographic variation in MO referral rates before (range: 5%-40%) and after cystectomy (range: 26%-59%). Patients seen by MO from 2004 to 2008 were more likely to receive ACT (57%) compared with patients in earlier years (41% in 1994-1998 and 46% in 1999-2003, P < 0.001). Conclusions: Lack of referral to MO is an important barrier to use of NACT/ACT. Upstream decision making by urologists is an important target in future knowledge translation. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1200 / 1208
页数:9
相关论文
共 30 条
[21]   Invasive Bladder Cancer: Ignoring the Data [J].
Raghavan, Derek .
ONCOLOGIST, 2013, 18 (08) :895-896
[22]   Understanding Avoidance, Refusal, and Abandonment of Chemotherapy Before and After Cystectomy for Bladder Cancer [J].
Rehman, Shabnam ;
Crane, Alice ;
Din, Rakeeba ;
Raza, Syed Johar ;
Shi, Yi ;
Wilding, Gregory ;
Levine, Ellis G. ;
George, Saby ;
Pili, Roberto ;
Trump, Donald L. ;
Guru, Khurshid A. .
UROLOGY, 2013, 82 (06) :1370-1375
[23]   Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population [J].
Schrag, D ;
Mitra, N ;
Xu, F ;
Rabbani, F ;
Bach, PB ;
Herr, H ;
Begg, CB .
UROLOGY, 2005, 65 (06) :1118-1125
[24]   Age and adjuvant chemotherapy use after surgery for stage III colon cancer [J].
Schrag, D ;
Cramer, LD ;
Bach, PB ;
Begg, CB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (11) :850-857
[25]  
Segal R, 2003, 321 CANC CAR ONT PRO
[26]  
Segal Roanne, 2002, Can J Urol, V9, P1625
[27]   Patterns of care for the treatment of bladder cancer [J].
Snyder, C ;
Harlan, L ;
Knopf, K ;
Potosky, A ;
Kaplan, R .
JOURNAL OF UROLOGY, 2003, 169 (05) :1697-1701
[28]   Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer [J].
Sternberg, Cora N. ;
Donat, S. Machele ;
Bellmunt, Joaquim ;
Millikan, Randall E. ;
Stadler, Walter ;
De Mulder, Pieter ;
Sherif, Amir ;
von der Maase, Hans ;
Tsukamoto, Taiji ;
Soloway, Mark S. .
UROLOGY, 2007, 69 :62-79
[29]  
Thompson RH, 2013, BJU INT
[30]  
Winquist E, 2005, 322 CANC CAR ONT PRO